MYRIAD GENETICS INC (MYGN) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US62855J1043
MYRIAD GENETICS INC financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 824.50 m USD |
| Gross profit | 576.60 m USD |
| Operating income | -387.20 m USD |
| EBIT | -386.40 m USD |
| Net income | -365.90 m USD |
| Diluted EPS – continuing operations | -3.95 USD |
Full history since 1995, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About MYRIAD GENETICS INC
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children's Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
More stocks
- Ichitan Group Public Company Limited (ICHI.BK)
- Ningbo MedicalSystem Biotechnology Co Ltd (300439.SZ)
- Hangzhou Zhengqiang Corporation Limited (301119.SZ)
- Tungkong Inc (002117.SZ)
- Hyliion Holdings Corp. (HYLN)
- Waga Energy SA (WAGA.PA)
- Shandong Teamgene Technology Co. Ltd. A (603151.SS)
- Guangdong Green Precision Components Co. Ltd. (300968.SZ)
- Sanyou Corporation Limited (300932.SZ)
- Changchun Gas Co Ltd (600333.SS)
- Optotech Corp (2340.TW)
- Petroreconcavo S.A (RECV3.SA)
Not investment advice. All data without warranty, price as of 09.11.2026. Details in the risk notice.